CAMBRIDGE, UK– 15 March 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has announced today that Paul Thompson, Chief Scientific Officer, will present at the Targeted Protein Degradation Europe Summit (16-18 March).
Paul Thompson will present on 18 March at 14:05 GMT, discussing how deubiquitylating (DUB) enzymes can be targeted for the treatment of human diseases. As an example, Paul will examine Mission’s lead in-house DUB inhibitor target, USP30.
The Targeted Protein Degradation Europe Summit was created with the goal of accelerating the translation of selective bioavailable and effective protein degraders into clinical trials. The Summit provides a platform of learning, discovery, and networking opportunities, to hear about the latest developments and advancements, and get invaluable guidance from leaders in the field of protein degradation. The event brings together over 100 biopharmaceutical professionals to capitalise on this emerging therapeutic class and make targeted protein degradation a blockbuster therapeutic approach that improves patient outcomes.
FOR MORE INFORMATION:
Mission Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel: +44 (0)1223 607 340
Melanie Toyne-Sewell / Katie Duffell
Tel: +44 (0) 20 7457 2013
NOTES TO EDITORS:
About Mission Therapeutics
Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.
Mission has strong links with key academic and research centers, including Prof. Steve Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company also has secured major industry partnerships, including its collaboration with AbbVie in November 2018, for the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease. The Company is managed by a team with broad international, commercial and clinical-science experience.
To date the Company has received £73 million /$101 million in funding and its investors comprise blue chip institutional and corporate investors including: Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group and Schroder Adveq. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.